Search for Clinical Trial Results
Lung Diseases, Interstitial - 29 Studies Found
Status | Study |
Recruiting |
Study Name: Pulmonary Rehabilitation in Interstitial Lung Disease Condition: Interstitial Lung Disease Date: 2005-09-13 Interventions: Behavioral: Pulmonary Rehabilitation |
Completed |
Study Name: Pulmonary Rehabilitation in Interstitial Lung Diseases Condition: Interstitial Lung Disease Date: 2009-04-15 Interventions: Other: Pulmonary Rehabilitation The intervention group will perform a 6 month pulmonary rehabilitation p |
Completed |
Study Name: Diagnostic Yield of Transbronchial Cryobiopsy in Diagnosis of Interstitial Lung Diseases Condition: Interstitial Lung Disease Date: 2014-08-26 Interventions: Other: Transbronchial lung cryobiopsy |
Active, not recruiting |
Study Name: Comparison of Transbronchial, Cryoprobe, and VATS Biopsy for the Diagnosis of Interstitial Lung Disease Condition: Interstitial Lung Disease Date: 2013-09-03 Interventions:
|
Recruiting |
Study Name: Comparison of Transbronchial, Cryoprobe and VATS Biopsy For the Diagnosis of Interstitial Lung Disease (ILD) Condition: Interstitial Lung Disease Date: 2013-06-27 Interventions:
|
COMPLETED |
Study Name: Study of Progression to Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Incidence/Management and Treatment Condition: Lung Diseases, Interstitial Date: 2024-05-17 |
COMPLETED |
Study Name: Oxygen Therapy Use in Patients With Fibrotic Interstitial Lung Disease Condition: Lung Diseases, Interstitial Date: 2024-05-17 |
RECRUITING |
Study Name: Physical Activity and Quality of Life in Fibrotic Lung Diseases After Initiating Anti-fibrotic Therapy and Pulmonary Rehabilitation Condition: Lung Diseases, Interstitial Date: 2024-05-17 Interventions: CP Insight Watch (Actigraph, Pensacola, FL) is usually worn on the wrist.The watch captures and records continuous high-resolution raw accelerat |
RECRUITING |
Study Name: A Single-cell Approach to Identify Biomarkers of Efficacy and Toxicity for ICI in NSCLC Condition: Lung Diseases, Interstitial Date: 2024-05-17 Interventions: Standard-of-care treatment for st.IV NSCLC (no driver mutation, PD-L1 > 50%) |